Senesco Logo
Home About Us News and Media Our Technologies Clinical Development Commercialization Investor Relations Contact Us
COMMERCIALIZATION
 
       
  > Therapeutics > Agriculture
  Therapeutics
Senesco’s eIF5A-based technology platform has proven relevant to human therapeutic and agricultural applications. The eIF5A gene and pathway are highly conserved among plants and animals. We have demonstrated ourselves and with collaborators that it functions similarly from plants to people. Our proprietary advantage and considerable know-how enable us to develop a series of innovative therapeutic candidates for treatment of multiple conditions, especially in cancer and inflammation.

Our current focus is on cancer, and specifically on multiple myeloma (MM) and other B-cell cancers including mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL). Our first product candidate, SNS01-T has been shown to inhibit the growth of and shrink tumors in animal models of human B-cell cancers, including multiple myeloma, mantle cell lymphoma and diffuse large B-cell lymphoma. We have seen effects in our Phase 1b/2a clinical study that suggest that SNS01-T may have beneficial effects on disease in patients suffering from multiple myeloma and diffuse large B-cell lymphoma.

  Disclaimer
facebook twitter youtube google+ linkedin